文献速递认知障碍与痴呆

APOE4与阿尔茨海默病临床变异同tau及淀粉样蛋白PET模式的关系

Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET.
PubMed 文献 · Neurology · 2020-12-01

研究纳入119例Aβ阳性的症状性阿尔茨海默病患者,采用PiB-Aβ和flortaucipir-tau PET成像,分析临床表型、年龄和APOE4与病理负荷及分布的关系。结果发现临床表型与tau病理模式相关而与淀粉样蛋白无关,APOE4与内侧颞叶tau局灶性增高相关。

要点

  • 临床表型与tau PET分布差异相关,与Aβ PET分布无关。
  • 年轻患者皮层tau结合更高,尤其顶叶和背侧前额叶。
  • APOE4携带者内侧颞叶tau SUVR局灶性增高。

核心结论

  • 临床表型与tau病理的差异模式相关,而与淀粉样蛋白病理无关。
  • 高龄和APOE4不仅是AD危险因素,还似乎通过促进内侧颞叶为主的tau病理模式影响疾病表达。

研究设计与样本

  • 研究纳入119例Aβ阳性的症状性患者,年龄48-95岁,包括29例logopenic变异型原发性进行性失语和21例后皮质萎缩。
  • 创建PiB-Aβ和flortaucipir-tau PET的SUVR图像,采用一般线性模型分析人口学/临床变量、APOE4与PET的关系,并用临床痴呆评定量表总分控制疾病严重程度。

主要发现

  • PiB-PET结合呈广泛皮层分布,表型间差异细微,与人口学/临床变量或APOE4无关。
  • Flortaucipir-PET在颞顶区域常见升高,但表型相关差异显著:后皮质萎缩在枕顶区结合更高,logopenic变异型原发性进行性失语在左颞和额下回更高,其他AD在内侧颞区更高。
  • 年轻患者皮层flortaucipir-PET结合更高(r = -0.63,95% CI -0.72,-0.50),尤其在顶叶和背侧前额叶皮层。
  • 控制所有其他变量后,APOE4与内侧颞叶flortaucipir-SUVR局灶性增高相关(内嗅皮层:+ 0.310 SUVR,95% CI 0.091,0.530)。

临床怎么用

  • 临床表型差异可能反映tau病理分布差异,支持tau PET用于区分AD变异型。
  • APOE4携带者及年轻患者tau PET表现不同,解读时应考虑年龄和基因型影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether Alzheimer disease (AD) clinical presentation and APOE4 relate to the burden and topography of β-amyloid (Aβ) and tau pathologies using in vivo PET imaging. METHODS: We studied 119 Aβ-positive symptomatic patients aged 48-95 years, including 29 patients with logopenic variant primary progressive aphasia (lvPPA) and 21 with posterior cortical atrophy (PCA). Pittsburgh compound B (PiB)-Aβ and flortaucipir (tau)-PET standardized uptake value ratio (SUVR) images were created. General linear models assessed relationships between demographic/clinical variables (phenotype, age), APOE4, and PET (including global cortical and voxelwise SUVR values) while controlling for disease severity using the Clinical Dementia Rating Sum of Boxes. RESULTS: PiB-PET binding showed a widespread cortical distribution with subtle differences across phenotypes and was unrelated to demographic/clinical variables or APOE4. Flortaucipir-PET was commonly elevated in temporoparietal regions, but showed marked phenotype-associated differences, with higher binding observed in occipito-parietal areas for PCA, in left temporal and inferior frontal for lvPPA, and in medial temporal areas for other AD. Cortical flortaucipir-PET binding was higher in younger patients across phenotypes (r = -0.63, 95% confidence interval [CI] -0.72, -0.50), especially in parietal and dorsal prefrontal cortices. The presence of APOE4 was associated with a focal medial temporal flortaucipir-SUVR increase, controlling for all other variables (entorhinal: + 0.310 SUVR, 95% CI 0.091, 0.530). CONCLUSIONS: Clinical phenotypes are associated with differential patterns of tau but not amyloid pathology. Older age and APOE4 are not only risk factors for AD but also seem to affect disease expression by promoting a more medial temporal lobe-predominant pattern of tau pathology.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. La Joie R, Visani AV, Lesman-Segev OH, et al. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology. 2020. PMID: 33262228. doi:10.1212/WNL.0000000000011270

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。